Buscar
Congreso SOLACI

Búsqueda de: TAVR

Si no está conforme con los resultados, inténtelo de nuevamente.
Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...
Dr. Juan Manuel Pérez -
Ir
Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...
Dr. Juan Manuel Pérez -
Ir
Structural Heart Disease

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...
Dr. Juan Manuel Pérez -
Ir
Structural heart disease

What Factors Predict Permanent Pacemaker Implantation after TAVR? CONDUCT-TAVI Outcomes

Permanent pacemaker implantation (PPM) for high grade atrioventricular block (AVB) continues to be one of the most...
Dr. Juan Manuel Pérez -
Ir
Structural heart disease

Is the Acceleration Time/Ejection Time Ratio Superior to the Mean Gradient in Predicting Clinical Outcomes After TAVR?

Courtesy of Dr. Juan Manuel Pérez. Traditionally, the mean gradient (MG) has been used to assess post-TAVR outcomes....
Dr. Juan Manuel Pérez -
Ir
Pharmacology

Can Colchicine Reduce Post-TAVR Conduction Disturbances?

Courtesy of Dr. Juan Manuel Pérez. Partly caused by perioperative inflammation, conduction disturbances often follow TAVR. Colchicine, known...
Dr. Juan Manuel Pérez -
Ir
Structural heart disease

Conduction Disorders in TAVR: Is Colchicine Useful?

TAVR has shown significant benefit and is increasingly used in severe aortic stenosis, especially in lower risk...
Dr. Carlos Fava -
Ir
Structural heart disease

Post TAVR Conduction Disturbances: Same Day Permanent Pacemaker Implantation

TAVR has consolidated as standard of care for aortic stenosis. In recent years, high volume centers have...
Dr. Omar Tupayachi -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad